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Abstract: The release of endogenous prostacyclin (PGI
2
) is depressed in patients with pulmonary
arterial hypertension (PAH). PGI
2
 replacement therapy by epoprostenol infusion is one of the 
best treatments available for PAH. Here, we provide an overview of the current clinical data for 
epoprostenol. Epoprostenol treatment improves symptoms, exercise capacity, and hemodynam-
ics, and is the only treatment that has been shown to reduce mortality in patients with idiopathic 
PAH (IPAH) in randomized clinical trials. We have reported that high-dose epoprostenol therapy 
(.40 ng/kg/min) also results in marked hemodynamic improvement in some patients with IPAH. 
High-dose epoprostenol has a pro-apoptotic effect on PAH-PASMCs via the IP receptor and 
upregulation of Fas ligand (FasL) in vitro. However, long-term intravenous administration of 
epoprostenol is sometimes associated with catheter-related infections and leads to considerable 
inconvenience for the patient. In the future, the development of new routes of administration or 
the development of powerful PGI
2
 analogs, IP-receptor agonists, and gene and cell-based therapy 
enhancing PGI
2
 production with new routes of administration is required.
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Background
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by 
progressive elevation of pulmonary vascular resistance (PVR) and pulmonary artery 
pressure (PAP) that leads to right heart failure and death. Increased PVR is induced 
by pulmonary vasoconstriction, vascular remodeling, and thrombosis.1,2 Those fac-
tors are associated with many molecules, substrates, and signaling pathways. Three 
pathways, namely prostacyclin (PGI
2
), nitric oxide (NO), and endothelin pathways, 
are critical for the pathogenesis and progression of PAH.3,4 Impaired production of 
vasodilators, such as PGI
2
 and NO, along with over-expression of vasoconstrictors, 
such as endothelin-1, play an important part in the pathogenesis of idiopathic PAH 
(IPAH).3 Drugs targeting the three pathways are currently available, and have been 
shown to be useful. In this review, we focus on the efficacy of high-dose epoprostenol 
sodium, a PGI
2
, for treatment of PAH.
Deficient endogenous PGI2 in PAH
An increase in the release of the vasoconstrictor thromboxane A2, suggesting the 
activation of platelets, occurs in patients with the primary form as well as those with 
the secondary form of pulmonary hypertension (PH). In contrast, the release of PGI
2
 is 
depressed in these patients.5 PGI
2
 synthase expression has been reported to be decreased 
in lung tissues from patients with severe PH.6 Whether the imbalance in the release 
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of these mediators is a cause or a result of PH is unknown, 
but this imbalance may play a part in the development and 
maintenance of both forms of the disorder.5
Protocol of epoprostenol therapy
We start epoprostenol therapy at a low dose  (0.25–0.5 ng/kg/min) 
and increase the dose daily by 0.25–2.0 ng/kg/min. When the 
dose of epoprostenol exceeds 10 ng/kg/min, we increase the 
dose weekly as previously described.7 Thereafter, we gradually 
increase the dose weekly or monthly to the maximal tolerated 
dose based on clinical symptoms and side effects in individual 
cases. We adjust the dose to match the change in body weight. 
Epoprostenol has a short half-life, and the in vivo half-life 
of epoprostenol in humans is expected to be no greater than 
6 minutes. Continuous intravenous administration by means 
of an infusion pump and a permanent tunneled catheter is 
needed for long-term treatment.8
When the patient develops right heart failure before 
the start of epoprostenol therapy, we initiate treatment 
with dobutamine and/or dopamine in our centers as pre-
viously described.9 We initiate dobutamine infusion at a 
low dose (3 µg/kg/min) when the patient’s mixed venous 
oxygen saturation (SvO
2
) is ,60% or cardiac index (CI) 
is ,2.0 L/min/m2 or when right ventricular (RV) failure is 
clinically suspected before the start of epoprostenol therapy. 
Clinical RV failure is defined as leg edema and jugular venous 
distention, heart enlargement in a chest radiograph (cardio-
thoracic ratio .50%), and a high level of brain natriuretic 
peptide (.100 pg/mL). If the value of SvO
2
 does not increase 
over 60% or CI does not increase over 2.0 L/min/m2 or if RV 
failure is not improved, the dose of dobutamine is titrated up. 
We initiate dopamine infusion at a low dose (3 µg/kg/min) 
when the patient’s systolic blood pressure (BP) is ,90 mmHg 
or urine volume is ,20 mL/h before the start of epoprostenol 
therapy. If systolic BP cannot be kept over 90 mmHg, the 
dose of dopamine is titrated up.
Efficacy of epoprostenol therapy
The efficacy of continuous intravenous epoprostenol therapy 
has been tested in three unblinded randomized clinical trials 
(RCTs) in patients with IPAH10,11 and in patients with PH 
due to the scleroderma spectrum of disease, WHO-functional 
class (WHO-FC) III or IV despite optical medical therapy.12 
Epoprostenol treatment improves symptoms, exercise capac-
ity, and hemodynamics, and is the only treatment that has 
been shown to reduce mortality of patients with IPAH in 
RCTs.11,13 Meta-analysis for total mortality in the three RCTs 
performed with the Mantel–Haenszel and Peto fixed-effect 
methods showed relative risk reductions of 70% and 68%, 
respectively.13 The fifth World Symposium on Pulmonary 
Hypertension (WSPH) in Nice, France in 2013 recommended 
continuous intravenous epoprostenol as first-line therapy for 
WHO-FC IV patients because of the survival benefit in this 
subset.13 McLaughlin et al reported the long-term efficacy of 
epoprostenol therapy in 162 patients with primary PH.14 After 
17 months, mean pulmonary pressure (mPAP) had decreased 
from 61±13 mmHg to 53±13 mmHg, and observed survival 
with epoprostenol therapy at 1–3 years was significantly 
greater than the expected survival based on historical data. 
Additionally, combination therapy with epoprostenol and 
bosentan improved the hemodynamics, functional class, 
and exercise capacity of IPAH, and anorexigen-associated 
PAH patients compared with those in matched controls who 
received epoprostenol monotherapy.15
In patients with PH due to the scleroderma spectrum 
of disease, continuous intravenous epoprostenol improves 
exercise capacity, hemodynamics, and survival compared 
with conventional therapy.12,16 Additionally, epoprostenol 
might improve the hemodynamics and survival in patients 
with PAH associated with connective tissue diseases (CTD), 
including mixed CTDs, CREST syndrome, systemic lupus 
erythematosus, scleroderma, and Sjogren syndrome.16–19
Rosenzweig et al reported the results of long-term epo-
prostenol therapy in patients with PH associated with con-
genital heart diseases (CHD-PAH).20 Twenty patients (eleven 
patients: previous cardiac surgery, eleven patients: residual 
systemic to pulmonary shunt, 15±14 years old) were treated 
with epoprostenol. mPAP had decreased from 77±20 mmHg 
to 61±15 mmHg one year after the start of treatment with 
epoprostenol at a dose of 82±37 ng/kg/min. Thomas et al 
also reported that long-term continuous PGI
2
 therapy in 
adult patients with CHD-PAH (37±10.5 years old) resulted 
in hemodynamic and clinical improvements.21
Epoprostenol therapy in patients with PH associated with 
portal hypertension improved hemodynamics but did not 
improve long-term survival.22–24
Long-term epoprostenol therapy in the dose range 
of 21–40 ng/kg/min reduced mPAP by 12%–22% and 
reduced PVR by 32%–53% compared with baseline val-
ues (Table 1).14,25,26 The dosage of epoprostenol is adjusted 
upward on the basis of symptoms of PAH and side effects 
of the drug. Since a chronic overdose of epoprostenol could 
lead to a high cardiac output state,27 the appropriate dose 
range of epoprostenol is thought to be 25–40 ng/kg/min on 
the basis of results of previous studies.3,14,25,26,28 However, 
treatment with epoprostenol at doses less than 40 ng/kg/min 
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mPAP (mmHg) PVR (wood units)
Before After Reduction (%) Before After Reduction (%)
McLaughlin et al25 27 40±15 16.7±5.2 67 52 -22 16.7 7.9 -53
McLaughlin et al14 115 34.5±30 17±15 61 53 -13 16.7 10.2 -39
Sitbon et al26 107 21±7 12 68 60 -12 37.3 25.4 -32
Akagi et al7 14 107±40 45±20 66 47 -30 21.6 6.9 -68
Note: Data are expressed as mean ± SD.
Abbreviations: mPAP, mean pulmonary pressure; PVR, pulmonary vascular resistance.












Figure 1 PGi2 induces apoptosis via upregulation of Fas ligand (FasL) in pulmonary 
artery smooth muscle cells (PASMCs) from patients with pulmonary arterial 
hypertension (PAH).
 sometimes cannot improve hemodynamics in patients with 
severe PAH. We reported that high-dose epoprostenol therapy 
(.40 ng/kg/min) caused marked hemodynamic improvement 
in 14 patients with IPAH.7 Compared with the baseline state, 
high-dose epoprostenol therapy reduced mPAP by 30% and 
PVR by 68% (Table 1), and increased CI by 89% and SvO
2
 
by 19%. Further studies are needed to clarify the efficacy of 
high-dose epoprostenol therapy (.40 ng/kg/min) in patients 
with PAH associated with CTD and CHD.
Reverse remodeling of pulmonary 
arteries by high-dose epoprostenol 
therapy
Increased PVR is induced by pulmonary vasoconstriction, 
vascular remodeling, including pulmonary vascular inti-
mal and medial thickening, and thrombosis.1,2 Intima and 
media thickening is largely composed of smooth muscle 
cells and myofibroblasts.29,30 Most cases of severe PH also 
exhibit a disorganized growth of primitive endothelial cells 
that form plexiform lesions.30 Enhanced proliferation and 
impaired apoptosis of pulmonary artery smooth muscle 
cells (PASMCs) cause an inappropriate increase in PASMCs 
and induce pulmonary vascular medial hypertrophy in 
PAH.31–35
Medical agents that have anti-proliferative and pro-
apoptotic effects on PASMCs are required for effective 
treatment that achieves reverse remodeling.35,36 PGI
2
 analogs 
have anti-proliferative effects on PASMCs in vitro.37 We have 
also reported that high-dose epoprostenol has a pro-apoptotic 
effect on PAH-PASMCs via the IP receptor and upregulation 
of Fas ligand (FasL) in vitro (Figure 1).38 In a case series, we 
examined the reverse pulmonary vascular remodeling effects 
of epoprostenol in lung tissues obtained from an IPAH patient 
treated with high-dose epoprostenol and an IPAH patient not 
treated with epoprostenol.39 Apoptotic cells were detected in 
small pulmonary arteries of the IPAH patient treated with 
high-dose epoprostenol (115 ng/kg/min) but not in those from 
the IPAH patient not treated with epoprostenol. The media of 
peripheral pulmonary arteries was thick in the IPAH patient 
not treated with epoprostenol. On the other hand, the media 
of peripheral pulmonary arteries was thin in the IPAH patient 
treated with high-dose epoprostenol. These results indicate 
that high-dose epoprostenol therapy has the potential for 
reverse pulmonary vascular remodeling by reduction of 
medial hypertrophy.
However, advanced proliferative vasculopathy after long-
term (18 years) and high-dose (60 ng/kg/min) epoprostenol 
therapy in a patient with IPAH was reported.40 There were 
frequent plexiform lesions adjacent to arterial branch points. 
Achcar et al also reported PGI
2
-treated cases that showed 
increased perivascular inflammation.41 Of note is the Stacher 
et al study on the impact of modern treatments of PAH, 
including treatment with PGI
2
 and its analogs, endothelin 
receptor antagonist (ERA), and phosphodiesterase type 5 
(PDE-5) inhibitors, on pulmonary vascular pathology.30 
Morphometric intima and media fractional thicknesses 
were significantly larger in the PAH group than in control 
lungs. Media fractional thickness was largely superimpos-
able with the range of media fractional thickness measured 
in normal pulmonary arteries. However, the overlap was 
less in intima fractional thickness, and marked perivascular 
inflammation was present in a large number of PAH lungs. 
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Furthermore, the number of profiles of plexiform lesions 
was significantly smaller in the lungs of patients who had 
never been treated with PGI
2
 or its analogs. These results 
indicate that epoprostenol therapy might reverse pulmonary 
vascular medial thickening but might not ameliorate intima 
thickening, perivascular inflammation, and plexiform lesions. 
Further studies to assess the reversal vascular remodeling 
effects of high-dose epoprostenol therapy are needed.
Acute vasoreactivity testing
Acute vasoreactivity testing is usually performed to predict 
a good prognosis and identify acute responders who are 
more likely to have a sustained beneficial response to oral 
calcium channel blockers (CCBs) and can be treated with 
these less-expensive drugs. Acute responders have been 
defined as patients who show a decrease in mPAP of at 
least 10 mmHg to an absolute level below 40 mmHg with 
preserved or increased cardiac output.42
Acute vasoreactivity testing is most commonly performed 
using intravenous epoprostenol,43,44 intravenous adenosine,45 
or inhaled nitric oxide.44 Acute testing using intravenous 
epoprostenol was shown to be useful for identifying patients 
with good prognosis; however, a good response to epopros-
tenol does not indicate that all patients will have a long-term 
response to CCBs.44,46,47 On the other hand, occurrence of 
life-threatening hemodynamic compromise has often been 
documented in CCB testing (nifedipine and verapamil).48–51 
Therefore, it is accepted that CCBs should not be used for 
acute testing.3,42 In contrast, intravenous CCB nicardipine 
might be useful for acute testing,52 because the drug is short-
acting compared to nifedipine and more vasoselective than 
other CCBs.53,54 We have reported that in 65 PAH patients 
administered low-dose nicardipine, there was no hemody-
namic instability requiring additional inotropic agents or 
death during the testing.52
Storage and stability
Unopened vials of epoprostenol sodium with  glycine-mannitol 
excipients (epoprostenol GM) are stable when stored at 
15°C-25°C (59°F–77°F), and protected from light in a 
carton. However, epoprostenol GM in solution has limited 
stability at room temperature. Prior to use, reconstituted 
solutions of epoprostenol GM must be protected from light, 
and must be refrigerated at 2°C-8°C (36°F–46°F) if not used 
immediately. During use, a single reservoir of reconstituted 
solution of epoprostenol GM can be administered at room 
temperature for a total duration of 8 hours or it can be used 
with a cold pouch and administered up to 24 hours with 
the use of two frozen 6-oz gel packs in a cold pouch. The 
need for refrigeration or the use of frozen gel packs during 
long-term administration leads to considerable inconve-
nience for the patient. Recently, epoprostenol sodium 
with arginine excipient has improved thermal stability. It 
might provide patients with an increased sense of treatment 
convenience.55,56
Adverse reactions
The most common adverse events (occurring in $10% of 
patients) during dose initiation were flushing, headache, 
 nausea/vomiting, hypotension, anxiety, and chest pain. 
The most common adverse events (occurring in $10% of 
patients) during chronic administration were dizziness, head-
ache, nausea/vomiting, jaw pain, myalgia, flushing, diarrhea, 
nonspecific musculoskeletal pain, tachycardia, chills/fever/
sepsis/flu-like symptoms, anxiety, and hypesthesia.
Chronic infusion of epoprostenol is delivered using a 
small, portable infusion pump through an indwelling central 
venous catheter. It results in limited improvement in quality 
of life. Catheter-related infections are problematic during 
long-term treatment. During long-term follow-up, sepsis 
was reported at a rate of 0.3 infections/patient per year in 
patients treated with epoprostenol. We have reported that the 
use of a closed hub system reduces catheter-related infec-
tions in patients with PAH receiving continuous therapy 
with epoprostenol at home.8 The development of new routes 
of administration is required in the future. Powerful PGI
2
 
analogs, IP-receptor agonists, or gene and cell-based therapy 
enhancing PGI
2
 production with new routes of administra-
tion are needed.57
Anticoagulation therapy is associated with a survival 
benefit in patients with IPAH and has been recommended.13,58 
Epoprostenol has antiplatelet activity, and has been reported 
to reduce the levels of plasma tissue-type plasminogen acti-
vator and plasminogen activator inhibitor.59 We previously 
reported that many hemorrhagic complications occur in 
patients with IPAH who receive both anticoagulation and 
epoprostenol treatment.60 Among 31 patients, nine had eleven 
bleeding episodes, nine (81.8%) of which were alveolar hem-
orrhages. Therefore, we have stopped using anticoagulation 




 replacement therapy by epoprostenol infusion is one of 
the best treatments available for PAH. High-dose epopros-
tenol therapy (.40 ng/kg/min) causes marked hemodynamic 
improvement in some patients with PAH.
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